Prot #KRT-232-104: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)

Project: Research project

Project Details

StatusFinished
Effective start/end date2/5/20 → 2/5/23

Funding

  • INC Research, LLC (Prot #KRT-232-104)
  • Kartos Therapeutics, Inc. (Prot #KRT-232-104)